Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rilimogene galvacirepvec
- Development stage
- Phase 2
- Lead developer
- Bavarian Nordic
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Subcutaneous
01
Overview
Rilimogene galvacirepvec (PROSTVAC-V) is a recombinant vaccinia virus-based cancer immunotherapy developed by the National Cancer Institute (NCI) in collaboration with Bavarian Nordic. It is designed to treat prostate cancer by inducing a targeted immune response against cells expressing prostate-specific antigen (PSA). The viral vector encodes the human PSA gene along with three costimulatory molecule transgenes—B7.1 (CD80), ICAM-1 (CD54), and LFA-3 (CD58)—collectively referred to as TRICOM. These molecules enhance the activation of T-cells by improving antigen presentation and signaling. In clinical practice, it is typically used as the 'prime' component of a heterologous prime-boost regimen, followed by 'boost' doses of rilimogene glafolivec (PROSTVAC-F), a fowlpox virus-based vector. While Phase II studies showed a significant overall survival benefit in patients with metastatic castration-resistant prostate cancer (mCRPC), the pivotal Phase III PROSPECT trial failed to meet its primary endpoint of improving overall survival compared to placebo.
- Brand names
- PROSTVAC
- Other names
- Recombinant Vaccinia-PSA/TRICOM Vaccine
02
Targets
CD58 (Leukocyte function-associated antigen 3)CD80 (T-lymphocyte activation antigen CD80)ICAM1 (Intercellular Adhesion Molecule 1)PSA (Puromycin-sensitive aminopeptidase)
Beyond the preview
Go deeper on rilimogene galvacirepvec.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rilimogene galvacirepvec.